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Abstract
Itch is one of the major complications of skin diseases. Although there are various substances that
induce itch or pruritus, it is evident that histamine is the best known endogenous agent that evokes
itch. Even though histamine-induced itch has been studied for some time, the underlying mechanism
of itch is just beginning to emerge. Although various downstream signaling pathways of histamine
receptors have been revealed, more studies are required to determine the cause of histamine-
induced itch. It appears that itch and pain involve different neuronal pathways. Pain generally inhibits
itch, which indicates an inter-communication between the two. Complex interactions between itch
and pain may be expected based on reports on disease states and opioids. In this review, we discuss
the molecular mechanism and the pharmacological aspects of histamine-induced itch. Especially, the
underlying mechanism of TRPV1 (an anti-pruritus target) has been determined to some extent.
Introduction
Itch is a sensation felt on skin, which causes the desire to
scratch. Although itch might constitute an alert system
against certain stimuli like mosquito bites, it can become
stressful and exhausting when excessive. Indeed, patients
with severe pruritus often find it difficult to lead a normal
life due to itch-associated psychological disturbances,
such as, depression or sleep deprivation [1,2]. Atopic der-
matitis patients suffer from severe itch, and this disease is
inadequately addressed by currently available medica-
tions. Therefore, an understanding of the mechanism of
itch is essential in order to treat severe symptoms.
Although numerous substances are known to cause pruri-
tus, such as, substance P, cytokines, proteases and so forth
(for a detailed review on pruritogenic agents, see [3,4]),
histamine is best known to evoke experimental itch when
applied to the skin [5-9]. Recent itch-related studies have
focused on non-histaminergic itch symptoms, but it is
also of considerable importance that we understand the
manner in which histamine induces itch. In this regard, it
is worth mentioning that antihistamines are among the
most widely-used drugs in the United States [10]. There-
fore, in this review, we will focus mainly on experimental
findings concerning histamine-induced itch.
Histamine and itch
Histamine is released from mast cells when tissues are
inflamed or stimulated by allergens [11,12], and once
released, histamine induces itch is triggered by the excita-
tion of a subset of unmyelinated C-fibers [13]. Histamine
receptors are known to mediate histamine-induced
responses, and are members of the G-protein-coupled
receptors. Four subtypes of histamine receptors have been
identified to date, and histamine receptor subtype I (H1R)
has been studied most extensively in the context of hista-
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are widely used to manage and alleviate itch symptoms
[14]. However, the itch-reducing efficacies of these classi-
cal H1R antihistamines are debatable because some
believe that the effect is attributable to sedation rather
than to H1R antagonism [15]. It appears that H1R antag-
onism does, at least to some extent, attenuate histamine-
induced itch, because non-sedative second generation
H1R antihistamines are beneficial for the management of
itch symptoms [16]. However, in contrast to the proven
relation between H1R and itch induction, the involve-
ment of histamine receptor subtype II (H2R) is less con-
vincing. It is generally believed that H2R is at best, only
marginally involved in histamine-induced itch process
[17,18]. For instance, dimaprit (a H2R agonist) failed to
cause scratching, and cimetidine (a H2R antagonist)
failed to suppress histamine-induced itch in BalbC mice
[19]. On the other hand, it is intriguing that histamine
receptor subtype III (H3R) "antagonists" aggravate itch
symptoms, which appears to contradict the aforemen-
tioned histamine-induced itch pathway [20]. For exam-
ple, the blockade of H3R by H3R-specific antagonists
(thioperamide or AQ0145) was found to significantly
increase the incidence of scratching behavior in mice [21].
Furthermore, intradermal injections of iodophenpropit or
clobenpropit (also H3R antagonists) caused significant
increases in scratching behavior in both mast cell-defi-
cient and wild-type mice [22]. Currently, it appears that
the itch elicited by H3 antagonism is mediated by sub-
stance P, another itch-inducing agent [23]. However, it
could also be mediated by mixed responses from H3R and
histamine receptor subtype IV (H4R), since clobenpropit
(a H3R antagonist) is also an agonist of H4R [24]. H4R
agonists cause scratching responses in mice, and are atten-
uated by pretreating animals with a selective H4R antago-
nist, like JNJ7777120 [25]. It is also noteworthy that
scratching behaviors are almost completely abolished
when H1R/H4R antagonists or H1 antagonist are co-
administered to H4R-knockout mice, which suggests that
H1R and H4R are key components of the itch response
[25].
Summarizing, it appears that activated H1R and H4R are
involved in the induction of itch, whereas H3R acts in the
reverse manner. On the other hand, it appears that H2R
has a minor role at most.
The histamine signaling pathway in sensory neurons
H1R is coupled with Gαq proteins, and this interaction
activates phospholipase C (PLC) [26]. In line with this, it
has been reported that histamine elevates calcium levels
in rat cultured sensory neurons, and that this elevation is
blocked by U73122 (a PLC inhibitor) [27]. Moreover, it
was recently found that PLCβ3 (and not the other PLC iso-
types) specifically mediates histamine-induced calcium
responses via H1R in cultured sensory neurons [28]. On
the other hand, stimulation of phospholipase A2 (PLA2)
by H1R was found to mediate histamine-induced sensory
neuron excitation [29,30]. Furthermore, Shim and col-
leagues showed that histamine induces itch by activating
PLA2, lipoxygenase, and the TRPV1 signaling pathway
[30]. Histamine induces inward currents that are blocked
by antagonists of TRPV1, a nonselective cation channel
stimulated by capsaicin [30,31]. They also demonstrated
that TRPV1 activation in sensory neurons by histamine is
mediated by the synthesis of 12-HPETE – a metabolite of
12-lipoxygenase and an endogenous TRPV1 activator
[30,32]. Moreover, histamine-induced scratching is
greatly reduced when inhibitors or blockers of H1R, PLA2,
12-lipoxygenase, or TRPV1 have been pre-treated. More
importantly, histamine-induced scratching is significantly
lower in TRPV1-deficient mice [30]. In line with this, the
direct intradermal injection of 12-HPETE (an endogenous
TRPV1 activator) was found to evoke scratching behaviors
in mice [33]. However, this 12-HPETE/TRPV1 linkage is
somewhat controversial, since 12-HPETE-induced
scratching in mice is not blocked by the TRPV1 antagonist
capsazepine [34]. However, 12-HPETE-induced scratch-
ing is reduced by topical application of capsaicin [33],
which is also known to cause desensitization of TRPV1.
More studies are required to determine whether 12-
HPETE/TRPV1 activation mechanisms participate in H1R-
related itch pathways.
It is well-known that H2R is involved in gastric acid secre-
tion, wherein the coupling of H2R and Gαs leads to cAMP
production [26]. However, as mentioned above, the role
of H2R in itch appears minor. H3R, on the other hand, is
linked to Gαi/o and the activation of H3R mainly inhibits
cAMP formation [35], but various down-stream signals
are also generated, such as, the activations of mitogen-
activated protein kinase (MAPK), PLA2, and others (For a
detailed review, see [36]). However, it should be noted
that H3R is predominantly expressed in the central nerv-
ous system, and was first identified in brain [37].
Although its existence in perivascular nerve terminals has
been suggested [38], it appears that H3R is not present in
the peripheral nervous system – at least in mice [23].
Therefore, the role of H3R in the mediation of histamine-
induced itch seems minor. However, interestingly, H3R is
regarded as a novel target for the treatment of obesity and
cognitive disorders [39,40].
The importance of H4R in terms of itch is becoming more
evident [41,42]. It is well known that the activation of
H4R increases intracellular Ca2+ levels; possibly in a phos-
pholipase C-dependent manner in mast cells [43]. More-
over, the existence of H4R in sensory neurons is suggested
by the observation that an intradermally administered
H4R-specific agonist elicited scratching in mice, whichPage 2 of 6
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onist, JNJ7777120 [25]. Thus, it seems likely that the acti-
vation of H4R results in the excitation of itch-mediating
histamine-sensitive afferents by increasing intracellular
Ca2+ levels, as mentioned above for the H1R pathway.
Neurophysiology of itch fibers
Most C fibers are polymodal nociceptors that respond to
noxious mechanical and heat stimuli (CMH units). These
CMH units are mainly related to nociception, but are
largely insensitive to or only weakly activated by hista-
mine [44]. In addition, histamine-sensitive C-fibers do
not respond to mechanical stimulation, which indicates
that these itch-mediating fibers differ from polymodal C-
fibers [45]. Indeed, these itch-mediating C fibers only
comprise about five percent of afferent C-fibers in human
cutaneous nerves [5]. Histamine activates a subset of C-
fibers that innervate the superficial layer of skin and trans-
mit electrical signals to the superficial layer of the dorsal
horn of the spinal cord [5]. These signals then ascend to
the thalamus through contralateral spinothalamic tracts
and are eventually conducted to the somatosensory and
cingulate cortex [46]. Interestingly, it was found that gas-
trin-releasing peptide plays a key role in mediating itch
sensation, rather than pain, by interacting with gastrin-
releasing peptide receptor (GRPR) at the spinal level [47].
Furthermore, the induction of scratching behavior in
response to pruritogenic stimuli was significantly dimin-
ished in GRPR knockout mice, but pain-related behavio-
ral responses to noxious stimuli were normal [47]. In
addition, direct spinal injection of a GRPR antagonist con-
siderably inhibited scratching behaviors [47]. Again, these
results provide support for the presence of a distinct itch-
mediating pathway. On the other hand, the itch elicited
by cowhage (a non-histaminergic pruritogen) appears to
be mediated through other distinct primary afferents [48]
and through cowhage-specific non-histaminergic spi-
nothalamic tracts [49]. Therefore, it seems that different
types of itch-mediating neurons coexist in the periphery.
Recently, the active compound in cowhage was identified
as a novel cysteine protease "mucunain", which is a ligand
for protease-activated receptors-2 and 4 [50]. Nakano et al
recently similarly concluded that different types of dorsal
horn neurons are associated with histamine-induced and
protease-activated receptor-2-mediated itch [51]. Thus, it
seems that there exist dedicated itch-mediating neuronal
pathways. Moreover, the recent identification of the co-
existence of histamine-sensitive and insensitive (or pro-
tease-related) pathways may provide some insight into
the mechanism of itch.
Painful stimuli inhibits itch sensation
We all share the experience that scratching relieves itching.
Furthermore, itch is also relieved when noxious heat is
administered [52]. In other words, itch can be suppressed
by painful mechanical and thermal stimuli. As stated
above, itch- and pain-inducing stimuli activate distinct
populations of sensory fibers, and thus, it is likely that
painful stimuli modulate itch sensations centrally and not
at the peripheral level. Histamine was found not to induce
itch when a noxious thermal stimulus was administered
within 10 cm, or to reduce itch severity if a noxious stim-
ulus was administered more than 10 cm away [53]. Nox-
ious cold also reduces pruritus when administered to
fingertips contralateral to a pruritic stimulus [54]. Moreo-
ver, various other painful stimuli, such as, noxious heat or
scratching, are known to inhibit histamine-induced itch
via central mechanisms [55-57].
In fact, capsaicin, the active ingredient of hot pepper, is
used as an anti-pruritic agent [58]. Capsaicin activates the
nonselective cation channel TRPV1, which is regarded to
induce nociception [31]. Thus, it is assumed that the anti-
pruritic effect of capsaicin is attributable to its algesic
effect. However, it should be noted that TRPV1 is
expressed in some histamine-sensitive itch-mediating fib-
ers as well as nociceptive C-fibers [30], which raises the
question; What types of processes are involved in the sen-
sation experienced when capsaicin is applied to the skin?
In most cases, pain is likely to be the predominant percep-
tion, since approximately 80% of the primary afferent C-
fibers are polymodal nociceptors [59-61]. In fact, the clin-
ical limitation of topical capsaicin administered as an
anti-pruritic agent is that it produces unbearable, burning
pain [58]. Furthermore, even if capsaicin excites TRPV1 in
itch fibers, the itch sensation may not dominate since
itch-mediating fibers comprise only small proportion of C
fibers [5]. Thus, although capsaicin may activate both
pain and itch through TRPV1 receptors in their respective
neurons, it is highly likely that capsaicin preferentially
activates nociceptive fibers.
However, it should also be noted that repeated and pro-
longed applications of topical capsaicin are required to
effectively reduce itch [62,63]. This method of application
is believed to fully desensitize and deplete neuropeptides,
such as, substance P in sensory afferents, and to thus delay
the interconnection between skin and sensory neurons
[58]. Indeed, it has been shown that repetitive application
of topical capsaicin prevents histamine-induced itch
under experimental conditions [64]. In this regard, it can
also be considered that the anti-pruritic effect of capsaicin
may stem from peripheral desensitization of sensory neu-
rons and central mechanisms.
Itch can also be suppressed by cold stimuli [65-67], and in
particular the anti-pruritic effect of menthol is interesting
[65], because menthol activates cold receptor TRPM8
[68,69]. However, although TRPM8 is a wonderful molec-
ular target, the mechanism whereby cold and mentholPage 3 of 6
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activated by noxious cold (<17°C), is also a viable target
[70]. but no concrete relationship between itch and
TRPA1 has been established. On the other hand, warming
appears to aggravate itch. Indeed, histamine-induced
response is potentiated by warming [67], but no clear
explanation has been offered as to how these thermal
stimuli interact with itch at the molecular level. It is note-
worthy that some TRP channels, like TRPV3 [71,72]
respond to warming, which suggests that they participate
in itch induction. However, no studies to date have
focused specifically on this topic.
Unfortunately, the relationships between itch and exoge-
nous stimuli in disease states appear anything but
straightforward. For instance, the itch-inhibitory effects of
repetitive scratching and noxious heat are ineffective in
patients with atopic dermatitis [73]. Similarly, the inhibi-
tory effect of topical capsaicin on histamine-induced itch
was found to be ineffective in atopic dermatitis patients,
but effective in healthy controls [64], indicating that other
factors are involved in disease states. Moreover, in con-
trast to our general understanding that cooling alleviates
itch, short-term low-intensity cooling increases the inten-
sity of histamine-induced itch above the scratch threshold
in man [74,75].
Interestingly, as a corollary to the suppression of itch by
painful stimuli, the reduction of pain by opioids may
induce itch [76]. Patients spinally administered μ-opioid
agonists frequently experience itch [77,78], whereas μ-
opioid antagonists often suppress experimentally-
induced itch [8,79]. However, not all opioids evoke itch,
for example, nalbuphine (a κ-opioid agonist) has been
shown to reduce μ-opioid-induced pruritus [80], and κ-
opioid antagonists enhance itch, which contrasts the
effects of μ-opioids [81]. Currently, it is unclear why dif-
ferent opioids have different effects on itch. Nevertheless,
it seems evident that itch can be enhanced when pain is
suppressed, and suppressed when pain is enhanced,
which demonstrates the existence of an intimate physio-
logic interaction between underlying causes of itch and
pain sensations.
Conclusion
Itch is probably viewed as trivial malady by most, but to
many patients itch is a distressing condition. Although it
has been revealed by many researchers that there is a his-
tamine-independent itch, this should not detract from the
fact that histamine is deeply involved in various itch sen-
sations. Recent advances in molecular biology have
helped reveal the key molecular players involved, but a
considerable amount of effort will be required to deter-
mine how histamine-induced itch is mediated and can be
inhibited. In our opinion, a thorough understanding of
the pruritogenic actions of histamine is required if we are
to resolved itch symptoms at the clinical level.
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